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Demyelination of the human peripheral nervous system (PNS) can be caused by diverse mechanisms including viral infection. Despite
association of several viruses with the development of peripheral demyelination, animal models of the condition have been limited to disease that
is either autoimmune or genetic in origin. We describe here a model of PNS demyelination based on direct injection of sciatic nerves of mice with
the cardiovirus, Theiler's murine encephalomyelitis virus (TMEV). Sciatic nerves of FVB mice develop inflammatory cell infiltration following
TMEV injection. Schwann cells and macrophages are infected with TMEV. Viral replication is observed initially in the sciatic nerves and
subsequently the spinal cord. Sciatic nerves are demyelinated by day 5 post-inoculation (p.i.). Injecting sciatic nerves of scid mice resulted in
increased levels of virus recovered from the sciatic nerve and spinal cord relative to FVB mice. Demyelination also occurred in scid mice and by
12 days p.i., hindlimbs were paralyzed. This new model of virus-induced peripheral demyelination may be used to dissect processes involved in
protection of the PNS from viral insult and to study the early phases of lesion development.
© 2006 Elsevier Inc. All rights reserved.Keywords: TMEV; Peripheral demyelination; Sciatic nerveIntroduction
Infectious agents are implicated in the development of
human peripheral demyelinating diseases such as Guillain–
Barre syndrome (Bitan et al., 2004; Takahashi et al., 2005;
Tababella and Nowzari, 2005; Ponticelli and Campise, 2005;
Koga et al., 2005; Izurieta et al., 2005). Diverse viral infections
have been associated with peripheral demyelinating disease
including those caused by cytomegalovirus (Tababella and
Nowzari, 2005), Epstein–Barr virus (Bitan et al., 2004;
Takahashi et al., 2005; Koga et al., 2005), human immunode-
ficiency virus-1 (Brannagan and Zhou, 2003), and varicella
zoster virus (Roccatagliata et al., 2001). Some cases of
peripheral demyelination have also been associated with viral
vaccinations (Izurieta et al., 2005; Khamaisi et al., 2004). These
reports cumulatively suggest that infection and/or the resulting⁎ Corresponding author. Fax: +1 402 280 1875.
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peripheral demyelinating disease in humans but despite this
strong inference, models used to study this condition involve
only autoimmune or genetic etiologies (Van Rijk et al., 2003;
Moon et al., 2006; Zhu et al., 2001; Bour-Jordan et al., 2005;
Meekins et al., 2004). Although current animal models
recapitulate certain forms of peripheral nervous system (PNS)
myelin loss (Van Rijk et al., 2003; Moon et al., 2006; Zhu et al.,
2001; Bour-Jordan et al., 2005; Meekins et al., 2004), none of
them describe virus-induced demyelination of PNS. This
prompted us to explore the possibility of establishing a murine
model to mimic this human condition.
Intracerebral (i.c.) inoculation of mice with Theiler's murine
encephalomyelitis virus (TMEV) is commonly used to study
viral demyelination and remyelination of the central nervous
system (CNS) (Drescher et al., 1998; Drescher et al., 2000a,b;
Dal Canto and Lipton, 1975; Lipton, 1975; Rodriguez, 1993;
Pena Rossi et al., 1997; Rodriguez et al., 1995; Rodriguez et al.,
1994a,b; Rodriguez and David, 1985). Because the pathologic
changes and subsequent clinical signs of the disease in mice are
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(MS), TMEV infection of mice is also used to model a
hypothetical viral etiology of MS (Dal Canto and Lipton, 1975;
Lipton, 1975). Demyelination is induced by TMEV-mediated
damage to CNS white matter (Lipton, 1975); chronic
demyelination is attributed to the development of autoimmune
responses to several myelin protein epitopes (Miller et al.,
1997a,b). Strains of TMEV belonging to the TO subgroup
(BeAn and Daniel's) induce acute encephalitis followed by
chronic demyelinating disease in susceptible strains of mice
(Lipton, 1975). The primary host determinant of demyelination
by TMEV is the murine haplotype: H-2b, H-2d mice are
resistant to TMEV-induced demyelination (Rodriguez et al.,
1993). Resistance or susceptibility to demyelination can also be
altered by deletion or depletion of CD8+ T cells (Rodriguez et
al., 1997) or CD4+ T cells (Rodriguez et al., 1997; Rodriguez
and Sriram, 1988), or by modulating a number of immune
system components (Rodriguez et al., 1995; Fiette et al., 1995;
Murray et al., 1998; Paya et al., 1990).
Natural TMEV infections of mice are spread via an oral/
fecal route of transmission (Theiler, 1940; Theiler and Gard,
1940). A likely route of infection following ingestion of the
virus involves the peripheral nerves of the gut (Ren and
Racaniello, 1992) whereby transport of virus to the CNS
could then establish a chronic demyelinating disease charac-
terized by inflammation and destruction of the myelin sheaths
surrounding the axons. We therefore used the sciatic nerve in
the leg (a relatively accessible peripheral nerve) as an
example of the PNS to determine whether TMEV injection
directly into the nerve would induce peripheral demyelination.
Following direct inoculation of sciatic nerves of female FVB
mice with TMEV, we observed demyelination coincident with
viral replication within the nerve. Virus subsequently spread
into the CNS. In immunodeficient scid mice, increased viral
replication and subsequent paralysis indicated a role for the
adaptive immune response in controlling PNS virus infection.
Because the precise site of initial virus inoculation is known,
this model can be used to study the earliest stages of lesion
development.
Results
TMEV is detected in sciatic nerves following direct injection
with virus
Initial demyelination is due to virus-induced damage in the
model of TMEV-triggered CNS demyelination (Dal Canto
and Lipton, 1975). To test whether TMEV could be
detectable in sciatic nerves following inoculation, FVB mice
were inoculated with 1×104 pfu/sciatic nerve (described in
Materials and methods). Briefly, the thigh musculature of the
mouse was separated to expose the sciatic nerve, into which
virus was injected directly using a 30 gauge needle. Injection
did not occur through the muscle itself. Mice were killed, the
nerve dissected, and then immunostaining of OCT-embedded
sciatic nerves was performed using a polyclonal TMEV
antiserum. At 3 days post-inoculation (p.i.), viral protein wasdetected in sciatic nerves of virus-injected (Fig. 1A), but not
HBSS-injected (control) mice (Fig. 1B). Earlier in infection,
virus positive cells were rarely detected in the sciatic nerve
(data not shown). To test whether we were detecting residual
protein from the virus inoculum, an equivalent amount of UV-
inactivated TMEV was prepared and injected as before into
sciatic nerves of FVB mice. UV-inactivation of virus was
confirmed by the inability of the virus to form plaques on an
L2 cell monolayer (data not shown). Examination of the
injected sciatic nerve by immunohistochemistry for the
presence of virus 3 days p.i. showed that viral protein was
not detected in the sciatic nerve of mice inoculated with UV-
inactivated virus (Fig. 1C).
To identify the cells associated with TMEV in the sciatic
nerve, we performed immunofluorescent staining on TMEV-
infected sciatic nerves from female FVB mice. A polyclonal
antiserum to TMEV was used, in combination with antibodies
specific for either macrophages or myelinating (Schwann) cells.
Markers of these cell types were chosen as macrophages have
been reported as a reservoir of TMEV in the CNS model of
demyelination (Clatch et al., 1990), and direct infection of
Schwann cells would support the ability of TMEV to induce
demyelination of the PNS. At 5 days post-infection, the time-
point where we observed maximal immunoreactivity for virus,
virus co-localized with markers for myelinated cells (Figs. 1D–
F), indicating that Schwann cells are infected following
intrasciatic nerve injection. This was not observed in control
mice; only myelin immunoreactivity was observed in the
uninfected (contralateral) sciatic nerves (Fig. 1G). To demon-
strate the specificity of the anti-myelin antibody, brain tissue
from a normal mouse was used as a control (Figs. 1H–I). The
cortex, an area of the brain rich in myelin (that is, a white matter
area) showed intense immunofluorescence (Fig. 1H). An
adjacent gray matter region which contains minimal numbers
of myelin-producing cells (the hippocampus) was devoid of
staining (Fig. 1H). Macrophages in the sciatic nerve of virus-
injected animals were also observed to be infected (data not
shown). Together, the immunostaining data suggest that TMEV
can productively infect the sciatic nerve of mice by this route of
infection.
Replicating virus can be isolated from sciatic nerves
We isolated sciatic nerve tissue from FVB mice 5 days p.i. and
assayed for infectious virus. At 5 days p.i., the adaptive antiviral
immune system has been triggered in mice when inoculated i.c.
with TMEV (Lindsley et al., 1991; Lindsay and Rodriguez, 1989).
Nerve tissue was homogenized, frozen and thawed, then tittered on
L2 cell monolayers. Titers of 5.0±0.7×104 TCID50 (n=3) per mg
nerve tissue were detected at this time-point. At an average weight
of 31 mg per dissected sciatic nerve, the total infectious viral load
in the dissected nerves at 5 days p.i. averaged 1.55×106±
2.2×101, an approximate 100-fold increase in titer over that which
was inoculated. Earlier in the infection (day 3 p.i.), sciatic nerve
titers were lower (9.1×104±0.5×101; n=3), supporting the
conclusion that replication was occurring in the sciatic nerve.
Prior to day 3, virus was rarely isolated from the sciatic nerve.
Fig. 1. Immunolocalization of TMEVantigens in the sciatic nerve of FVBmice. Virus antigen positive cells are apparent in sciatic nerves at 3 days post-infection of the
sciatic nerve with TMEV; staining of a TMEV-injected sciatic nerve is shown in panel A. Dark reaction product indicates positive staining (examples shown by white
arrowhead). No immunoreactivity was observed in the sciatic nerve of an HBSS-injected mouse (B). Following injection of UV-inactivated virus into the sciatic nerve,
viral proteins were not detected by immunohistochemistry (C). Slides were stained using the ABC Methodology as described previously (Drescher et al., 1998).
Development was carried out using DAB. Double immunofluorescent staining was performed using markers specific for myelinating cells (D, F, G) combined with
identification of TMEV (E) as described in Materials and methods. Single channel images are shown (D, E) as well as merged images (F, G). Staining is shown for
sciatic nerves from FVB mice at 5 days post-inoculation (D–F). A merge image of the uninfected contralateral sciatic nerve is negative for TMEV (G). Controls
included staining a normal mouse brain with the antibody to myelinating cells to demonstrate specificity for white matter areas of the brain (H). A DAPI image of the
brain is shown for comparison purposes (I). Original magnification ×480 (A–C), ×1000 (D–G), ×80 (H, I).
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below the level of detection of the assay, which is about 3×103 per
mg. As similar results were obtained in SJL/J mice (data not
shown), the results observed are unlikely to be solely a function of
the genetic background of the mice.
It has been established that TMEV replicates to higher titers
in the CNS of scid mice, which lack functional B and T cells
(Bosma et al., 1983), than in immunocompetent mice following
i.c. inoculation (Drescher et al., 1999; Njenga et al., 2004). We
hypothesized that TMEV would similarly generate higher titers
in sciatic nerve tissue of scid mice if the adaptive immune
response was involved in protection of the sciatic nerve. Scid
mice were inoculated with 1×104 pfu per sciatic nerve, then
killed 5 days later. We observed an increase of more than 4 logs
in viral titer in sciatic nerves of the scid mice (3.2±5.1×109
TCID50/mg nerve tissue) relative to immunocompetent FVB
mice. These results indicated that the adaptive immune responseplays a critical role in protection of mice inoculated with TMEV
via the sciatic nerve.
Inflammatory cells infiltrate TMEV-injected sciatic nerves
Inflammatory cells are not detected in normal PNS or CNS
(Male et al., 1992; Male et al., 1990a,b; Wekerle et al., 1986) but
damage to either the PNS or CNS can culminate in the
recruitment of inflammatory and/or immune cells to the site of
injury (Male et al., 1990a, 1992). Lymphocytic infiltration of
the brain in the TMEVmodel of CNS demyelination is apparent
by 3–5 days p.i. (Lindsay and Rodriguez, 1989; Lindsley et al.,
1988); the tissue is infiltrated by T and B cells as well as
macrophages (Lindsley et al., 1988).
Immunohistochemical staining was used to examine whether
immune cells were recruited during TMEV replication in
the sciatic nerve. Sciatic nerves were dissected from FVB
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described previously (Drescher et al., 2004). Inflammatory
cells were not observed in uninjected sciatic nerves from
control, unmanipulated mice (data not shown) but macro-
phages (Fig. 2A) and T cells (Fig. 2B) were detectable in
TMEV-inoculated nerve tissue. HBSS-injected (mock-inocu-
lated) sciatic nerve tissue was also negative for inflammatory
cells at the same time point (Figs. 2C, D). B cells were not
detected in any sample (data not shown). The absence of
immune cells in HBSS-inoculated sciatic nerves indicates that
the recruitment of inflammatory cells to virus-containing
sciatic nerve tissue was not attributable to the physical insult
of the injection process but occurred in response to a specific,
sustained viral insult to the sciatic nerve.
TMEV spreads from the sciatic nerve (PNS) to the spinal cord
(CNS)
Studies utilizing poliovirus (Solomon and Willison, 2003;
Sabin and Ward, 1941; Sabin, 1956), herpes simplex virus
(Hemachudha et al., 2005; Faber et al., 2004; Song and Jia,
1999; Fujiki and Tashiro, 1997), and rabies virus (Hemachudha
et al., 2005; Faber et al., 2004) have shown that virus can be
transported to the CNS during viral replication following
infection of the PNS. We therefore asked whether TMEV was
also capable of spreading from the PNS to the CNS following
direct injection of the sciatic nerve. At day 3 post-injection, no
virus was detected in the spinal cords of either FVB or scidmice
(sensitivity of plaque assay, 200 pfu/g tissue). Seven daysFig. 2. Immunostaining for immune cells in the sciatic nerves of virus (A, B) and co
detected in sciatic nerves of virus-injected FVB mice (examples shown by white arr
nerve of control, HBSS-injected female FVB mice. Markers used to identify these ce
the ABC immunoperoxidase technique as described (Materials and methods). Dev
positive staining. Original magnification ×480.following sciatic nerve injection of scid mice with TMEV, we
detected 2.4±0.8×106 pfu/g (n=3) TMEV in the spinal cord,
while a hundred fold lower viral titers detected in the spinal
cords (6.4±1.7×103 pfu/g; n=3) of FVB mice again indicated
a role of the adaptive immune system in suppressing TMEV
replication in this system. The differences in viral titers between
FVB and scid mice are similar to those that have been reported
in the CNS following intracerebral injection with TMEV
(Njenga et al., 1997).
We also determined whether mice were functionally
impaired following sciatic nerve injection with virus. Scid
mice first demonstrated hindlimb paralysis 12 days after
sciatic nerve injection with TMEV, although FVB mice
appeared showed no altered movements or activity levels at
the same time-point relative to mock-infected control mice.
Neither scid nor FVB mice were maintained longer than
16 days p.i. These results indicate that virus is transported
from the PNS to the CNS following injection of TMEV into
the sciatic nerve and that in the absence of a functional
adaptive immune response, the virus induces sufficient
damage to the nervous system which can result in functional
alterations and eventually death.
PLP levels are altered and demyelination is induced following
TMEV infection of the sciatic nerves
Injury to myelin-producing cells results in alterations in
mRNA levels of genes involved in myelination (Gupta et al.,
1991; Yaghootfam et al., 2005; Kawczak et al., 1998; Ozdenntrol (C, D) injected mice. At day 4 p.i., macrophages (A) and T cells (B) were
owhead). Neither macrophages (C) nor T cells (D) were identified in the sciatic
ll types were F4/80 (macrophages) and CD3 (T cells). Slides were stained using
elopment was carried out using DAB. Dark colored reaction product indicates
Fig. 3. Real-time RT-PCR demonstrates that PLP mRNA levels peak at day 3
post-injection of the sciatic nerve with TMEV (solid circles). A 4.9±0.5-fold
relative increase in PLP mRNA levels is evident as early as 2 h after sciatic nerve
injection with TMEV (solid circles; p=0.02). By day 3 p.i., PLP transcript
levels peak, with a 15.7±2.7-fold increase in mRNA levels as compared to
uninjected control sciatic nerves (p<0.032). This increase in PLP mRNA levels
begins to subside by day 5 p.i. with virus, but still remains 3.1±0.3-fold higher
than baseline levels (p=0.02). Additional control mice were injected with HBSS
(open circles) into the sciatic nerve. No significant alterations in PLP mRNA
levels were observed over 5 days. Standardization was performed using GAPDH
as a housekeeping gene. Real-time PCR was performed using TaqMan
methodology (Materials and methods) on an ABI 7000 SDS Sequence
Detection System (Applied Biosystems).
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following virus insult, an increase in transcription of genes
encoding myelin components should be detectable. However,
if demyelination occurred in the absence of remyelination, a
decrease in transcripts associated with the production of
myelin proteins might be the result of either death and/or
damage to myelin-producing cells. In the CNS model of
TMEV-induced demyelination, myelin proteolipid protein
(PLP) transcripts in spinal cord have been shown to be
altered relatively within hours following TMEV-induced
injury (Rodriguez et al., 1994a,b). We injected sciatic nerves
of FVB mice with virus to test whether injection of TMEVFig. 4. Pathology of the sciatic nerve of virus-injected (B, C) and HBSS-injected (A)
myelin around the axons; infiltrating cells are absent (A). Mice injected with TME
presents as paler circles versus the dark well-myelinated axons). In addition, the s
macrophages (thin, white arrow) as well as myelin debris (thin black arrow). Sciatic
were stained with 4% para-phenylenediamene (PPD) and examined by light microsinto the sciatic nerve altered levels of PLP gene transcripts in
the sciatic nerve. RNA was isolated from dissected sciatic
nerves at various time-points after injection, and real-time RT-
PCR performed utilizing primers and a dual-labeled fluoro-
genic probe for PLP. Real-time PCR was standardized to a
housekeeping gene (glyceraldehyde-3-phosphate-dehydroge-
nase, GAPDH) (Medhurst et al., 2000). Data are expressed as
the fold-increase in PLP mRNA level relative to the levels of
PLP mRNA in uninjected (control) sciatic nerves. A signi-
ficant increase in the level of PLP mRNA was observed
within 2 h post-injection compared to uninfected controls
(4.9±0.5-fold-increase over control; p=0.02). However, al-
though there was an increase in PLP mRNA abundance over the
following 24 h, the differences between the points were not
significant (1.8±0.4-fold over baseline; p<0.2) (Fig. 3). By
72 h p.i., a 15.7±2.7-fold increase (p<0.032) in transcript
levels had occurred in virus-injected sciatic nerve tissue relative
to the level in uninjected control mice (Fig. 3). PLP mRNA
levels then decreased to a 3.1±0.3-fold increase over control by
day 5 p.i (p=0.02). To determine whether sustained inflamma-
tion was required for alterations in PLP mRNA levels, PLP
mRNA abundance was also measured in sciatic nerves of mock-
infected female FVB mice (injected with HBSS). No significant
alterations in PLP mRNA levels were detected relative to the
uninjected sciatic nerve over the course of the experiment
(5 days; Fig. 3), results that indicated that putative transient
inflammatory responses which may be induced by injecting the
nerve with physiologic salt solution, are inadequate for PLP
transcript levels to be altered in the sciatic nerve. Together, these
results are consistent with the induction of myelin repair
processes in the virus-injected sciatic nerves within hours of
virus infection.
Demyelination of the sciatic nerve is observed following
injection with TMEV
As the observation that PLP mRNA levels were increased in
TMEV-inoculated sciatic nerves was consistent with activation
of a myelin repair mechanism in response to the viral insult, we
performed histopathological analyses of sciatic nerves from
virus-injected mice for evidence of demyelination. Osmicatedmice. HBSS-injected sciatic nerves are characterized by uniform, well-preserved
V (B, C) show demyelination of the axons (thick white arrow; demyelination
ciatic nerve contains cells which, due to their foamy appearance, appear to be
nerves were osmicated, embedded in plastic, and 1 μm sections prepared. Slides
copy. Original magnification ×1200.
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previously were stained with para-phenylenediamene (PPD),
then examined for evidence of myelin loss; HBSS-injected
sciatic nerves served as controls. Sciatic nerves injected with
HBSS appeared histologically normal, characterized by uni-
form, well-preserved myelin around the axons (Fig. 4A).
However, extensive myelin loss was observed in sciatic nerves
of TMEV-inoculated mice (Figs. 4B, C). Demyelination of
sciatic nerves of TMEV-inoculated mice was distinguished by
loss of myelin around the axons (thick, white arrows, Figs. 4B,
C), by the presence of cellular debris (thin black arrows, Fig.
4C) and by cells that appear to be foamy macrophages,
indicating that the macrophages are engaged in cleaning cellular
debris (thin, white arrows, Fig. 4C). These results demonstrate
that demyelination occurs as a result of the productive TMEV
infection occurring in sciatic nerves following direct inoculation
with virus.
Discussion
Results presented here describe a novel model of virus-induced
peripheral demyelinating disease. Following inoculation of TMEV
directly into the mouse sciatic nerve, infectious virus transits to the
CNS. Detection of increased virus loads demonstrate productive
virus replication occurs in inoculated nerves. Demyelination of the
sciatic nerve was related to the presence of replicating virus for no
demyelination was observed in mock-infected nerves. Demyelin-
ation could be the result of direct infection of myelinating cells
and/or due the in resulting immune response. This model should
have relevance for testing putative infectious etiologies of human
nervous system diseases such as Guillain–Barre syndrome and
multiple sclerosis, as well as for studies of PNS remyelination. In
our model of virus-induced peripheral demyelinating disease, only
virus-injected (not mock-infected) sciatic nerves were infiltrated
by immune cells, indicating that immune cell recruitment to the
sciatic nerve requires sustained, specific stimuli. Observations in
scid mice demonstrated TMEV achieved higher viral titers than
in immunocompetent FVBmice, suggesting a role for the adaptive
immune system in virus suppression and likely, virus clearance.
These results may be relevant to the human condition in instances
of severely immunosuppressed individuals experiencing periph-
eral demyelinating diseases (Rao and Thomas, 2005; Hulgan et al.,
2005; Ferrari et al., 2006). An advantage of the model presented
herein is that the site of the initial damage is known, thus allowing
for the study of the beginning phases (that is, minutes or hours after
insult) of lesion development and repair—processes that are
typically difficult to study in vivo. One can speculate that this
model may also be applicable for studies of viruses that may not
replicate well when injected into mice: direct injection of
infectious virions into the sciatic nerve may induce a host response
of interest and might also provide a productive microenvironment
for the virus to replicate in an otherwise refractory host.
Early work (Rustigian and Pappenheimer, 1949) demon-
strated that injection of TMEV into the leg muscle resulted in
flaccid paralysis, initially observed in the injected leg and
subsequently in the uninfected leg. Naturally occurring TMEV
infections occur via the fecal–oral route; in some cases virustransits to the CNS with subsequent paralysis (Theiler, 1940;
Theiler and Gard, 1940). Such spread of virus from the
alimentary tract to the CNS could be via peripheral nerves and/
or blood (Ren and Racaniello, 1992). Although the receptor for
TMEV remains unknown, one potential receptor for TMEV is
P0, a protein structurally consistent with other picornavirus
receptors (Libbey et al., 2001; Mendelsohn et al., 1989;
Bernhardt et al., 1994) and thought to be confined to the PNS
(Libbey et al., 2001). Schwann cells, the cell responsible for
myelination of the PNS, are susceptible to infection by diverse
viruses including TMEV (Watanabe et al., 2006; Jin et al.,
2004; Tanimura et al., 2004; Levine et al., 2003; Nien et al.,
1998; Libbey et al., 2001; Frankel et al., 1986). Based on the
literature, there was no a priori reason to doubt that such
peripheral infections indeed can and do occur naturally and
could be modeled in experimental systems. Indeed, polio has
been well-studied with regard to its transport from the
periphery to the CNS (Ren and Racaniello, 1992; Ohka
et al., 1998).
We hypothesize that following TMEV injection of the sciatic
nerve, Schwann cells are infected and demyelination occurs
through death of Schwann cells or impairment of their ability to
produce myelin. Once Schwann cells are infected, replicating
virus can be transported to the spinal cord. The mechanism of
transport to the spinal cord has not been elucidated, but based on
the literature axonal transport is one potential mechanism
(Martinat et al., 1999). In contrast to the situation observed by
others (Martinat et al., 1999) using the neurovirulent GDVII
strain, immunocompetent mice in our studies did not experience
overt clinical deficits (i.e., slowed movement, paralysis, death)
associated with virus infection. The differences in clinical
presentation between our studies and the previous studies could
be attributed to either different cell types becoming infected in
the spinal cord, or to altered viral loads. Despite the high degree
of genetic identity between the GDVII and DA strains of TMEV
(Pevear et al., 1988; Pevear et al., 1987), these TMEV strains
preferentially infect different cell types in the CNS. GDVII
localizes primarily in gray matter, while DA establishes
infection primarily in white matter. Several reports ascribe the
differences in virus localization in the mouse CNS to differences
in receptor usage (Shah and Lipton, 2002; Jnaoui et al., 2002;
Tsunoda et al., 2001; McCright et al., 1999; Zhou et al., 2000;
Jnaoui and Michiels, 1999).
Previous work has shown that TMEV, strain GDVII, can be
transported from the periphery to the CNS via fast axonal transport
within 48 h of footpad inoculation (Martinat et al., 1999).
Although the impact of the virus infection on myelin integrity was
not explicitly addressed in this study (Martinat et al., 1999), it was
noted that pathologic changes were reported in the gray matter of
the spinal cord once virus was in the CNS, implying minimal
involvement of white matter areas of the CNS and PNS. Strain
GDVII is considered highly neurovirulent and has not been shown
to infect white matter areas of the CNS in vivo; a characteristic
attributable to differences in receptor usage by the GDVII and TO
viruses (Tsunoda et al., 2001; Jnaoui et al., 2002).
The majority of studies involving virus infection of the PNS
have studied cases of human peripheral dysfunction (Ferrari et
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et al., 2001; Khamaisi et al., 2004; Ponticelli and Campise,
2005; Izurieta et al., 2005). The PNS is extremely efficient at
remyelination: our results showed increases in myelin PLP
mRNA levels beginning within 2 h of infection with a peak
increase in PLP mRNA at 72 h p.i. These results indicate that a
rapid stimulation of the processes involved in protection of the
myelin sheaths occurs following TMEV injection. Thus, we
hypothesize that demyelination may well have occurred in
human cases of peripheral neuropathy attributed to infection
with particular viruses but was unable to be observed as myelin
repair mechanisms were rapidly invoked.
In summary, the results presented herein introduce a new
murine model for studying pathogenic mechanisms of virus-
mediated peripheral nerve demyelination. The ability to study
lesion dynamics in the context of both myelin damage and
repair is a unique character of this model. The model may
additionally be utilized to study the roles of the immune system
in limiting demyelination as well as repairing damage to the
PNS. A greater understanding of these processes could permit
better treatment of conditions associated with viral infections of
the PNS in humans.
Materials and methods
Virus
TMEV, strain DA, is a prototypic demyelinating strain of the
TO subgroup; the disease observed in the CNS following
infection with TMEV/DA has been extensively described
(Drescher et al., 1998, 2000a,b; Dal Canto and Lipton, 1975;
Lipton, 1975; Lipton and Dal Canto, 1976; Pena Rossi et al.,
1991, 1997; Lipton and Dal Canto, 1977, 1979; Rodriguez and
David, 1985). TMEV was propagated in BHK cells as
previously described (Rodriguez et al., 1986), collected by
freeze-thaw lysis. Following removal of cellular debris by
centrifugation (Beckman SW28.1, 25,000×RPM, 8 °C, 30min),
the virus was collected by overnight ultracentrifugation through
30% w/v sucrose, 100 mM NaCl, 20 mM Tris–HCl pH 7.5, into
a glycerol pad. Virus was suspended in Hank's Balanced Salt
solution (HBSS), tittered on BHK monolayers (pfu/mL), and
stored frozen in aliquots at −80 °C. Titers are measured either by
pfu/mL or TCID50/mL. In some experiments, UV-inactivated
TMEV was used. Undiluted virus stock was placed under a UV
light for 10 min. An aliquot of the virus was assayed on an L2
cell monolayer to ensure inactivation; lack of cytopathic effect
was used as an indicator of inactivation. The same stock of virus
was used for all experiments.
Mice
Female mice (FVB or B6.CB17-Prkdcscid/SzJ) were pur-
chased from Jackson Laboratories (Bar Harbor ME) at 6 weeks
of age. Mice were housed at 5 per cage in Thoren Maxi-Miser
System cages (Hazelton, PA) and provided food and water ad
libitum. The entire cage set including food and water was steam
sterilized prior to use. Cages were changed weekly.Injection of the sciatic nerve
Mice were anesthetized using IsoFlo (Abbott Laboratories,
North Chicago, IL), the hindleg wetted with 95% ethanol, skin
cut, and muscle moved to expose the sciatic nerve, per
published methodology (Palmer et al., 2000). Mice were kept
on a warming pad which aids in reduction of stress by helping
the mouse to maintain proper body temperature during the
procedure. A 30 gauge needle attached to a Hamilton syringe
(Fisher Scientific, St. Louis, MO) was used to inject the sciatic
nerve with 10 μL of virus diluent (Hanks' Balanced Salt
Solution, HBSS) containing 2×104 pfu of TMEV. Mock-
infected, control animals were injected with 10 μL HBSS.
Wounds were closed using surgical staples (MikRon® AUTO-
CLIP® 9 mm, Becton Dickinson, Sparks, MD) and the wound
site treated with triple anti-bacterial ointment. Actetaminophen
was added to the drinking water (80 mg/5 mL) as a post-
operative analgesia.
All animal experiments were performed in accordance with
guidelines of the Association for Accreditation and Assessment
of Laboratory Animal Care (AAALAC), the Creighton
University Institutional Animal Care and Use Committee
(IACUC), and Federal regulations.
Tissue collection
Mice were killed with an injection of 100 μL sodium
pentobarbital (Sleepaway, Fort Dodge Animal Health, Fort
Dodge, IA) i.p. Mice were then perfused with 4% paraformal-
dehyde in phosphate-buffered saline (PBS) (Drescher et al.,
2000a,b). Sciatic nerves and spinal columns were dissected
and placed in 4% paraformaldehyde in PBS at room
temperature. In some cases, tissues were snap frozen under
dry ice for RNA extraction or virus tittering, or embedded in
OCT Frozen Embedding Media (Miles, Inc., Elkhart, IN) for
immunostaining.
Immunostaining
Six micron thick sections of tissue embedded in OCT Frozen
Embedding Media (Miles, Inc.) were cut and fixed in chilled
acetone. Sections were stained with monoclonal antibodies to
CD4 (BD Pharmingen, San Diego, CA), CD8 (BD Pharmin-
gen), F4/80 (Chemicon, Temecula, CA) or a polyclonal antisera
to TMEV using the avidin–biotin complex (ABC) immunoper-
oxidase technique (Vector Laboratories, Inc., Burlingame, CA)
as described previously (Drescher et al., 1999). Development
was performed using the DAB Substrate Kit (Vector Labora-
tories, Inc.). Slides were lightly counterstained with Mayer's
hematoxylin (Sigma), dehydrated, and mounted with Permount
(Fisher Scientific).
Additional slides were stained using immunofluorescence.
OCT-embedded sections were stained with primary antibodies
to TMEV, and a monoclonal antibody to either F4/80
(Chemicon) or myelin (Clone HPC-7; Biosource, Saco, ME).
Visualization was performed using Alexa-Fluor-labeled sec-
ondary antibodies (Molecular Probes/Invitrogen, Carlsbad, CA)
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Coverslips were applied using Vectashield Mounting Media
with DAPI (Vector Labs).
Viral infectivity
Sciatic nerves and spinal cords were dissected from mice at
various times post-infection and tissue was stored at −80 °C
until used. Plaque assays were performed on spinal cord tissue
samples as described previously (Patick et al., 1990) while titers
in sciatic nerve tissue were expressed as TCDI50/g nerve tissue
(Tracy et al., 2002). In each case, a minimum of three samples
were assayed per time point.
Real-time PCR
RNA was isolated using Trizol (Invitrogen, Carlsbad, CA)
from snap frozen sciatic nerves at various times p.i. per the
manufacturer's instructions. Real-time PCR was performed
using dual-labeled fluorogenic TaqMan probes (Medhurst et
al., 2000; Khademi et al., 2004). The reporter dye 6-carboxy-
fluorescein (FAM) is attached to the 5′ end of the probe, and
6-carboxy-tetramethyl-rhodamine (TAMRA) to the 3′ end of
the probe. Primers and probes were obtained/produced from
Applied Biosystem's Assays-by-Design Service. The primers/
probes used are as follows: PLP: forward (5′→3′): CGC
TGT CAG GCA GAT CTT TG; PLP: reverse (5′→3′):
TGC GCT CAG GCC CTT G; PLP probe (5′→3′): ACT
ACA AGA CCA CCA TCT GC. Assays and data analysis
were performed using the ABI 7000 SDS Sequence Detec-
tion System (Applied Biosystems); five replicates of each
sample were run. All data were reported as fold-increase (or
decrease) compared to control. Relative changes in mRNA
levels were determined using the difference in the cycle
threshold value (ΔCT method) (Medhurst et al., 2000;
Khademi et al., 2004).
Sciatic nerve morphology
Sciatic nerves were stored in 4% paraformaldehyde for at
least 1 week after perfusion prior to processing the samples for
plastic embedding. Samples were osmicated and embedded in
Epon 812 plastic (Electron Microscopy Sciences, Hatfield, PA)
as described previously (Drescher et al., 2000a,b). One micron
sections were cut, stained with 4% PPD and cover-slipped.
Sections were examined by light microscopy.
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